Phase 1 Obesity Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are male or female, aged between 50 and 70 years old at the time of signing the consent form.
- People whose Body Mass Index (BMI) — a measure based on height and weight — falls between 30.0 and 39.9 at the initial screening visit.
- People whose excess body weight is considered by the investigating doctor to be due to excess body fat rather than another cause.
- People who want to lose at least 25% of their body weight within 52 weeks of treatment.
Who may not be able to join:
- People who have had any leg amputations.
- Female participants who have not yet reached menopause at the time of screening.
- People who have had a significant change in body weight of 5% or more (based on self-reporting), or who have made dieting attempts, within the 90 days before screening.
- People who have been treated with a GLP-1 receptor agonist medication — a type of drug sometimes used for blood sugar control or weight management — or any medication with similar activity, within the 90 days before screening.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Transparency dept. 2834, Novo Nordisk A/S
Phone: (+1) 866-867-7178
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in insulin-stimulated fluorodeoxyglucose (FDG) uptake in skeletal muscle
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.